

**Maricopa Integrated Health System
Formulary Prior Auth Criteria**

Drug: Zetia (ezetimibe)

Therapy:

Is indicated for the treatment of elevated total cholesterol, LDL cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. It is a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol.

Inclusion:

- Failure of formulary HMG-CoA reductase inhibitors in the past 30 days
- Failure/contraindication (i.e. myalgia, increase in CPK, history of rhabdomyolysis, liver dysfunction)/allergic response to HMB-CoA reductase inhibitors
- Nutritional counseling and diet restrictions of saturated fat and cholesterol
- Lab work

Risk Factors/Contraindication:

- Use with caution in patients with mild hepatic insufficiency
- Potential for increase in liver function tests
- Caution should be used in pregnancy and nursing women- Pregnancy Class C
- Hypersensitivity to any component of this medication.
- Due to unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, Zetia is not recommended in these patients.

Authorization:

Initially three months

Longer authorization of one year with documentation efficacy

Medical Director_____

Date_____